Breast最新文献

{"title":"Trajectories and predictors of financial toxicity in breast cancer patients: A multicenter longitudinal study in China","authors":"Yi Kuang ,&nbsp;Jiajia Qiu ,&nbsp;Ye Liu ,&nbsp;Sijin Guo ,&nbsp;Ting Chen ,&nbsp;Lichen Tang ,&nbsp;Winnie K.W. So ,&nbsp;Weijie Xing","doi":"10.1016/j.breast.2025.104441","DOIUrl":"10.1016/j.breast.2025.104441","url":null,"abstract":"<div><h3>Background</h3><div>Patients with breast cancer experience varying levels of financial toxicity (FT), but the factors contributing to sustained financial toxicity remain poorly understood.</div></div><div><h3>Methods</h3><div>This longitudinal study was conducted from November 2022 to March 2024 in China. Participants were recruited from four Tertiary Level A hospitals using convenient sampling. FT was assessed using the Comprehensive Score for Financial Toxicity (COST) at baseline (T1), 3 months (T2), 6 months (T3), and 12 months (T4) post-surgery. Growth Mixture Modeling was used to identify the different trajectories of the FT. Multivariable logistic regression were employed to explore the predictive factors with different trajectory categories.</div></div><div><h3>Results</h3><div>Among 378 participants (all women; median [SD] age, 48.9 [9.97] years), the COST score was lowest at T2. Three distinct FT trajectories were identified: 91 patients <strong>(24 %)</strong> in the \"Severe FT with Gradual Relief\" group (trajectory 1), 190 patients <strong>(50 %)</strong> in the \"Persistently Low-Level FT\" group (trajectory 2), and 97 patients <strong>(</strong>26 %<strong>)</strong> in the \"Moderate FT with Gradual Worsening\" group (trajectory 3). Using trajectory 2 as the reference, predictors for trajectory 1 included symptom burden, location, cancer stage, cost-related health literacy, resilience, and difficulty affording basic expenses. For trajectory 3, predictors included monthly household income, symptom burden, location, and cancer stage.</div></div><div><h3>Conclusions</h3><div>The FT experienced by breast cancer patients changes over time and follows distinct dynamic trajectories, influenced by multiple factors. In future clinical practice, early identification and intervention for high-risk FT groups should be prioritized.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104441"},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying germline pathogenic variants in breast cancer using tumor sequencing","authors":"Mara Cruellas ,&nbsp;Andri Papakonstantinou ,&nbsp;Adrià López-Fernández ,&nbsp;Ester Castillo ,&nbsp;Judit Matito ,&nbsp;Marina Gómez ,&nbsp;Alejandra Rezqallah ,&nbsp;Sharela Vega ,&nbsp;Víctor Navarro ,&nbsp;Maite Torres ,&nbsp;Alejandro Moles-Fernández ,&nbsp;Cristina Saura ,&nbsp;Ana Vivancos ,&nbsp;Judith Balmaña ,&nbsp;Mafalda Oliveira","doi":"10.1016/j.breast.2025.104439","DOIUrl":"10.1016/j.breast.2025.104439","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the performance of an in-house tumor sequencing panel to identify patients with breast cancer and a germline pathogenic variant (gPV).</div></div><div><h3>Patients and methods</h3><div>Retrospective and blinded tumor sequencing analysis in 90 patients with breast cancer and prior germline genetic testing (45 non-carriers and 45 carriers of a gPV) using an in-house panel (VHIO-300). Sensitivity (S), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) of tumor sequencing were calculated. A Cohen's kappa coefficient ≥0.80 was predefined as minimum to be reliably acceptable for clinical implementation.</div></div><div><h3>Results</h3><div>The cohort included 84 women and 6 men with a median age of 48 years (29–84). Tumors of germline carriers were mainly stage II (47 % vs 31 %, P = 0.047), luminal B-like (56 % vs 31 %, p = 0.037) or triple negative (22 % vs 16 %, = 0.037). The in-house tumor panel identified 91 % (40/44) of the gPV. The analysis did not detect any of the 2 patients with germline large rearrangement alterations nor 2 of the 7 patients with intronic variants included. The tumor sequencing panel yielded 7 % of false positive results (ie, genetic alterations suggestive of germline origin). Hence, S was 91 %, Sp 93 % and Cohen's kappa coefficient between tumor and germline testing was 0.84 (95 % CI 0.73–0.95).</div></div><div><h3>Conclusion</h3><div>Tumor tissue sequencing with our in-house panel demonstrated an acceptable performance to identify patients with breast cancer carriers of a gPV.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104439"},"PeriodicalIF":5.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early prediction of cardiovascular events following treatments in female breast cancer patients: Application of real-world data and artificial intelligence","authors":"Quynh T.N. Nguyen ,&nbsp;Shwu-Jiuan Lin ,&nbsp;Phung-Anh Nguyen ,&nbsp;Phan Thanh Phuc ,&nbsp;Min-Huei Hsu ,&nbsp;Chun-Yao Huang ,&nbsp;Chin-Sheng Hung ,&nbsp;Christine Y. Lu ,&nbsp;Jason C. Hsu","doi":"10.1016/j.breast.2025.104438","DOIUrl":"10.1016/j.breast.2025.104438","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104438"},"PeriodicalIF":5.7,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143703956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer","authors":"Joyce O'Shaughnessy ,&nbsp;Sara M. Tolaney ,&nbsp;Denise A. Yardley ,&nbsp;Lowell Hart ,&nbsp;Pedram Razavi ,&nbsp;Peter A. Fasching ,&nbsp;Wolfgang Janni ,&nbsp;Lee Schwartzberg ,&nbsp;Julia Kim ,&nbsp;Murat Akdere ,&nbsp;Courtney McDermott ,&nbsp;Aamir Khakwani ,&nbsp;Purnima Pathak ,&nbsp;Stephanie L. Graff","doi":"10.1016/j.breast.2025.104437","DOIUrl":"10.1016/j.breast.2025.104437","url":null,"abstract":"<div><h3>Background</h3><div>Despite adjuvant endocrine therapy (ET), recurrence is still a concern for patients with HR+/HER2- early breast cancer (EBC). We assessed recurrence risk in real-world patients with stage II/III HR+/HER2- EBC treated with adjuvant ET.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted using the ConcertAI Patient360 database (January 1995 to April 2021) of patients with stage II/III HR+/HER2- EBC ≥18 years who underwent surgery and received adjuvant ET. Risk of recurrence was assessed using invasive disease-free survival (iDFS) with adapted STEEP criteria. An ET subanalysis evaluated iDFS, distant disease-free survival, and overall survival in patients receiving adjuvant non-steroidal aromatase inhibitors (NSAI) vs tamoxifen.</div></div><div><h3>Results</h3><div>In the full analysis cohort (N = 3133), the risk of an iDFS event was 26.1 % at 5 years, rising to 45.0 % at 10 years. Among patients with stage II disease, the risk of an iDFS event at 5 and 10 years was 22.7 % and 40.5 %, respectively; stage III 5- and 10-year risk was 40.4 % and 62.9 %. Patients with node-negative disease had 5- and 10-year risks of 22.1 % and 36.9 %, respectively; node-positive 5- and 10-year risk was 28.9 % and 49.4 %. ET subanalysis showed improved iDFS with NSAI ± ovarian function suppression vs tamoxifen ± ovarian function suppression (HR, 0.83; 95 % CI, 0.69–0.98; p = 0.031); this trend was observed regardless of menopausal status.</div></div><div><h3>Conclusions</h3><div>This real-world study highlights the considerable risk of recurrence with adjuvant ET in patients with stage II or III HR+/HER2- EBC (including node-negative disease) and confirms the need for improved treatment options.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104437"},"PeriodicalIF":5.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143714552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integration of translational research in phase III trials: A systematic review of breast cancer studies in a 5-year period","authors":"G. Giannone ,&nbsp;P. Lombardi ,&nbsp;M. Filetti ,&nbsp;J. Paparo ,&nbsp;C. Rognone ,&nbsp;S. Stefanizzi ,&nbsp;A.A. Valsecchi ,&nbsp;L. Zumstein ,&nbsp;I.A. McNeish ,&nbsp;D.J. Pinato ,&nbsp;A. Gennari ,&nbsp;G. Daniele ,&nbsp;M. Di Maio","doi":"10.1016/j.breast.2025.104431","DOIUrl":"10.1016/j.breast.2025.104431","url":null,"abstract":"<div><h3>Background</h3><div>Samples' collection for translational analyses in phase III trials requires a huge effort and there is no evidence on how it translates into new knowledge on tumour biology or optimization of patients’ selection. We systematically reviewed phase III trials in breast cancer (BC) to evaluate how frequently a translational project has been integrated into their design and how this integration translated into new translational evidence.</div></div><div><h3>Methods</h3><div>Interventional phase III trials evaluating anticancer drugs in BC published in 11 major journals between 2014 and 2018 were included.</div></div><div><h3>Results</h3><div>89 BC phase III trials were identified, 3 had no sample collection. Among the others, in 36 % the information on sample collection for research purposes was not clear while more than half of the samples had definitive evidence of it.</div><div>After a median follow-up of 87.9 months, 55.8 % studies published translational data with a mean number of 1.31 (SD 1.7) and 1.07 (SD 1.8), congress abstracts and secondary papers, respectively.</div><div>There was a higher probability of published translational results for studies with positive outcomes (68.6 % vs 47.1 %), clear evidence of sample collection (72.2 % vs 28.1 %), well-established translational endpoint (73 % vs 42.9 %) and higher impact factor journal (IF) for the clinical publications (64.5 % vs 33.3 %). Secondary translational papers were usually published in lower IF journals with a significant delay from the clinical publication.</div></div><div><h3>Conclusions</h3><div>Although extremely resource-demanding, sample collections for translational analyses in phase III trials are frequently not well defined, and only 50 % produce new translational evidence, which is delayed in time and published in lower IF journals.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104431"},"PeriodicalIF":5.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2− early breast cancer","authors":"Wolfgang Janni ,&nbsp;Michael Untch ,&nbsp;Nadia Harbeck ,&nbsp;Joseph Gligorov ,&nbsp;William Jacot ,&nbsp;Stephen Chia ,&nbsp;Jean-François Boileau ,&nbsp;Subhajit Gupta ,&nbsp;Namita Mishra ,&nbsp;Murat Akdere ,&nbsp;Andriy Danyliv ,&nbsp;Giuseppe Curigliano","doi":"10.1016/j.breast.2025.104429","DOIUrl":"10.1016/j.breast.2025.104429","url":null,"abstract":"<div><h3>Background</h3><div>Current standard of care for patients with HR+/HER2− early breast cancer (EBC) includes adjuvant endocrine therapy with an aromatase inhibitor (AI) or tamoxifen (TAM). We present a trial-level meta-analysis on efficacy of AI vs TAM in patients with HR+/HER2− EBC.</div></div><div><h3>Methods</h3><div>A systematic literature review was conducted using key medical literature databases (eg, PubMed; inception to October 2023) and data from conferences (to December 2023). Phase 3 randomized controlled trials (RCTs) that had ≥80 % of patients with HR+/HER2− EBC (or available subgroup data) and reported a disease-free survival (DFS) hazard ratio for AI vs TAM were included in the meta-analysis, regardless of menopausal status and ovarian function suppression (OFS) use. The generic invariance method was used to calculate a pooled effect estimate of DFS hazard ratios and 95 % CIs. A base-case analysis (all RCTs) and scenario analyses for NSAI-only, premenopausal, and postmenopausal RCTs were conducted.</div></div><div><h3>Results</h3><div>Five RCTs were identified for inclusion in the meta-analysis. In the base-case analysis, DFS significantly favored AI ± OFS vs TAM ± OFS (pooled hazard ratio, 0.68; 95 % CI, 0.61–0.76; <em>P</em> &lt; .0001). Results from scenario analyses were consistent with the base case; NSAI-only (pooled hazard ratio, 0.68; 95 % CI, 0.59–0.78; <em>P</em> &lt; .0001), premenopausal (pooled hazard ratio, 0.65; 95 % CI, 0.56–0.76; <em>P</em> &lt; .0001), and postmenopausal (pooled hazard ratio, 0.72; 95 % CI, 0.61–0.86; <em>P</em> = .001) RCTs favored AI ± OFS over TAM ± OFS.</div></div><div><h3>Conclusions</h3><div>This trial-level meta-analysis demonstrated a significant DFS benefit with AI vs TAM for patients with HR+/HER2− EBC, which was more pronounced in premenopausal women.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104429"},"PeriodicalIF":5.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143704592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Awareness of genomic testing among patients with breast cancer in Europe","authors":"Antonella Cardone ,&nbsp;Dany Bell ,&nbsp;Conchi Biurrun ,&nbsp;Francesco Cognetti ,&nbsp;Fatima Cardoso ,&nbsp;Ana Ramirez Piris ,&nbsp;Csaba Degi ,&nbsp;Michael Patrick Lux ,&nbsp;Richard Simcock ,&nbsp;Johanna Wassermann ,&nbsp;Rosanna D'Antona ,&nbsp;Isabel T. Rubio","doi":"10.1016/j.breast.2025.104436","DOIUrl":"10.1016/j.breast.2025.104436","url":null,"abstract":"<div><h3>Purpose</h3><div>Genomic testing, involving expression profiling of tumour tissue, is a powerful tool for determining appropriate treatments for certain cancer patients. This study aimed to evaluate awareness of genomic testing in breast cancer patients in five European countries.</div></div><div><h3>Methods</h3><div>The survey was initiated by Cancer Patients Europe and developed with patient associations, oncologists, and a psycho-oncologist. Participants were recruited via email and social media and completed a 42-question internet survey.</div></div><div><h3>Results</h3><div>Of 1383 participants in eligible countries completing the survey, 566 women with current or previous HR+/HER2- breast cancer, potentially eligible for genomic testing, were analysed. 245 (43.3 %) were aged 50–59 years and 381 (67.3 %) had received higher education. 238 participants (42.1 %) had heard about genomic testing; 122 (21.6 %) were informed of their eligibility for testing, and 104 (18.4 %) were given reasons for the test. The majority (N = 479; 84.6 %) felt they lacked sufficient information to decide, and only 139 (24.6 %) opted for testing. Overall, 246 (43.5 %) wanted more information on additional testing and 234 (41.3 %) wanted more information on treatment options. The main information sources were medical professionals (N = 363; 64.1 %) and the internet (N = 351; 62.0 %). However, 398 participants (70.3 %) indicated that their healthcare professionals did not advise them on where to find more information.</div></div><div><h3>Conclusions</h3><div>This study highlights insufficient awareness of, and access to, genomic testing in breast cancer. Healthcare professionals need to improve communication with patients regarding genomic testing and involve them in shared decision-making. Likewise, patient associations have a role in providing clear information to patients.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104436"},"PeriodicalIF":5.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between decision regret, quality of life, and mindfulness in early-stage breast cancer survivors","authors":"Yu-Ling Kao ,&nbsp;Ming-Shen Dai ,&nbsp;Wan-Chen Tsai ,&nbsp;Fei-Hsiu Hsiao","doi":"10.1016/j.breast.2025.104435","DOIUrl":"10.1016/j.breast.2025.104435","url":null,"abstract":"<div><h3>Purpose</h3><div>The shared decision-making empowers breast cancer patients’ autonomy in joining treatment decision. However, unexpected side effects or unsatisfactory outcomes can lead to decision regret. This study examines decision regret levels and its relationship with quality of life, and the impact of mindfulness awareness and self-compassion on this relationship among early-stage breast cancer patients in post-treatment survivorship.</div></div><div><h3>Methods</h3><div>A cross-sectional study was conducted from March 2021 to March 2022. The early-stage breast cancer patients who completed treatments within the past 36 months were recruited from a medical center and a regional hospital. Participants completed the Decision Regret Scale, Mindful Awareness Attention Scale, Self-Compassion Scale, and the EORTC QLQ-C30 and QLQ-BR45.</div></div><div><h3>Results</h3><div>Among the 138 participants, 17.39 % reported no regret, 55.80 % expressed mild regret, and 26.81 % reported moderate to strong regret. Decision regret differed significantly based on the congruence between patients’ preferred and actual decision-making roles. Multiple regression analysis showed that, after controlling for covariates, lower decision regret levels were associated with higher EORTC QLQ-C30 and QLQ-BR45 function scores. Mindfulness awareness significantly mediated the relationship between decision regret and QOL, while self-compassion was not identified as a mediator.</div></div><div><h3>Conclusion</h3><div>Most breast cancer survivors experienced mild or moderate decision regret. Decision regret influences survivors’ general and breast specific functions. Mindfulness awareness could reduce the impact of decision regret on QOL. The mindfulness-based interventions could cultivate breast cancer patients living at the present moment experiences to reduce their negative rumination about the past treatment decision and enhance their QOL.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104435"},"PeriodicalIF":5.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)","authors":"Maeve A. Hennessy ,&nbsp;Ashley Cimino-Mathews ,&nbsp;Jodi M. Carter ,&nbsp;Jennifer M. Kachergus ,&nbsp;Yaohua Ma ,&nbsp;Jeffrey P. Leal ,&nbsp;Lilja B. Solnes ,&nbsp;Vandana G. Abramson ,&nbsp;Lisa A. Carey ,&nbsp;Mothaffar Rimawi ,&nbsp;Jennifer Specht ,&nbsp;Anna Maria Storniolo ,&nbsp;Christos Vaklavas ,&nbsp;Ian Krop ,&nbsp;Eric Winer ,&nbsp;Rita Denbow ,&nbsp;Vincente Valero ,&nbsp;Antonio C. Wolff ,&nbsp;Richard L. Wahl ,&nbsp;Chiung-Yu Huang ,&nbsp;Roisin M. Connolly","doi":"10.1016/j.breast.2025.104432","DOIUrl":"10.1016/j.breast.2025.104432","url":null,"abstract":"<div><h3>Background</h3><div>Early metabolic change on PET/CT was predictive of response to neoadjuvant trastuzumab/pertuzumab (HP) in TBCRC026. We hypothesized that a composite biomarker incorporating PET/CT and HER2 tissue-based biomarkers could improve biomarker performance.</div></div><div><h3>Methods</h3><div>83 patients with estrogen receptor-negative/HER2-positive breast cancer received neoadjuvant HP alone [pathologic complete response (pCR) 22 %]. PET/CT was performed at baseline and 15 days post initiation of therapy (C1D15). Promising imaging biomarkers included ≥40 % SULmax decline between baseline and C1D15, and C1D15 SULmax ≤3. Baseline tissue-based biomarkers included HER2-enriched intrinsic subtype (72 %, 46/64; NanoString), tumor HER2 protein abundance (median log2 13.5, range log2 7.1–15.9; NanoString DSP), and HER2 3+ (83 %, 64/77; immunohistochemistry). Logistic regressions were fitted to predict pCR with HER2/PET-CT biomarkers. The C statistic assessed overall prediction power. The optimal composite score cut-off was determined by maximizing Youden's index.</div></div><div><h3>Results</h3><div>Factors most predictive for pCR in single predictor models included C1D15 SULmax (OR 0.43; p = 0.007, c = 0.77), % reduction in SULmax (OR 1.03, p = 0.006, c = 0.72) and tumor HER2 protein abundance (OR 1.75; p = 0.01, c = 0.76). The composite of C1D15 SULmax and % reduction in SULmax and their interaction term, had improved probability (c = 0.89 from c = 0.78), with high sensitivity (100 %) and negative predictive value (100 %). The addition of tumor HER2 protein did not further improve prediction power (c = 0.90).</div></div><div><h3>Conclusion</h3><div>The HER2/PET-CT biomarker had high prediction power for pCR, however was not superior to the prediction power of PET/CT alone. Non-invasive PET/CT biomarkers may facilitate a response-guided approach to neoadjuvant therapy, allowing intensification and de-intensification of treatment, pending further evaluation.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104432"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143550255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovations in the localization techniques for non-palpable breast lesions: Make invisible visible","authors":"Quankun Lin ,&nbsp;Qiwen Hou ,&nbsp;Chenyu Zhang ,&nbsp;Wei Zhai ,&nbsp;Feng Cheng ,&nbsp;Sen Lu ,&nbsp;Xuan Yang ,&nbsp;Aiping Dong ,&nbsp;Baosan Han","doi":"10.1016/j.breast.2025.104430","DOIUrl":"10.1016/j.breast.2025.104430","url":null,"abstract":"<div><div>Non-palpable breast cancer lesions pose a challenge for surgeons to resect cancer lesions. Making ‘invisible’ lesions ‘visible’ is the main strategy. Currently, multiple preoperative localization techniques have been applied in clinical. Among them, wire-guided localization (WGL) is the most common procedure due to its convenience and low cost. However, its limitations including discomfort, wire migration and the coupling of localization and operation procedures cause troubles for surgeons and patients. The desire for localization methods improvement, accompanied by the advance of emerging science and technology, leads to the development of a series of locating approaches for breast non-palpable lesions, aiming to improve locating accuracy while reducing adverse events. These emerging methods have undergone improvements from steel wire to functional particles, from radioactivity to non-radioactive, which help doctors and patients choose a more appropriate scheme. This review outlines the principles, procedures, advantages and disadvantages of these locating methods, and highlights the latest progress and related clinical data on innovative locating approaches. Finally, we briefly discuss the current challenges and future opportunities for the clinical application of these localization approaches.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104430"},"PeriodicalIF":5.7,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}